6/30/2021 10:02:24 AM
Kazia Updates On Paxalisib And EVT801 Clinical Programs
6/15/2021 10:04:09 AM
Kazia Collaborates With Cornell University For Phase II Study Using Paxalisib-Ketogenic Diet For Glioblastoma
6/7/2021 8:29:01 AM
Kazia Therapeutics Enrols First Patient In Phase II Study Of Paxalisib In Primary CNS Lymphoma
4/19/2021 5:39:51 AM
Evotec Grants Kazia Worldwide License To Develop, Manufacture, And Commercialise EVT801
3/29/2021 5:21:08 AM
Kazia Therapeutics Enters Licensing Agreement With Simcere Pharmaceutical To Develop Paxalisib
12/10/2020 10:02:24 AM
Kazia To Collaborate With Pacific Pediatric Neuro-Oncology Consortium For Paxalisib Combination Study In DIPG
12/9/2020 10:37:38 AM
Cantrixil Phase I Study Confirms Prior Positive Efficacy & Safety Signals In Persistent/recurrent Ovarian Cancer
10/16/2020 10:32:01 AM
Kazia Executes Deal To Commence GBM Agile Pivotal Study
9/22/2020 10:07:23 AM
Kazia Reaches Clinical Collaboration With Dana-farber Cancer Institute For Primary CNS Lymphoma
8/23/2020 8:55:04 PM
FDA Awards Orphan Drug Designation To Paxalisib For Malignant Glioma, Including DIPG
8/20/2020 10:32:04 AM
Kazia : FDA Awards Fast Track Designation To Paxalisib For Glioblastoma
8/7/2020 10:32:29 AM
Kazia Therapeutics : FDA Grants Rare Pediatric Disease Designation To Paxalisib For DIPG